Class II · Moderate risk
Progesterone 200 mg Capsules 90 capsules
Lack of Processing Control
FDA drug recalls in 2020
Every FDA drug recall initiated in 2020, newest first, with its risk class, status and the reason the FDA recorded. Use the cause and risk filters to narrow the year down.
930 recalls, newest first.
Class II · Moderate risk
Progesterone/Versa Base 20 mg
Lack of Processing Control
Class II · Moderate risk
Bi-Est (1:1)
Lack of Processing Control
Class II · Moderate risk
Bi-Est (1:1)
Lack of Processing Control
Class II · Moderate risk
Bi-Est (8:2)
Lack of Processing Control
Class II · Moderate risk
Bi-Est (1:1)
Lack of Processing Control
Class II · Moderate risk
Estradiol 1.8 mg capsule 30 cap bottle
Lack of Processing Control
Class II · Moderate risk
Testosterone w/ Atrevis 100 mg/mL GEL
Lack of Processing Control
Class II · Moderate risk
Testosterone w/ Atrevis 20 mg
Lack of Processing Control
Class II · Moderate risk
Estradiol Vag Cream 0.01% Cream 30 gm tube
Lack of Processing Control
Class II · Moderate risk
Estradiol/Progesterone/Testosterone 1.5/100/1.25 mg/mL Cream 30 gm tube
Lack of Processing Control
Class II · Moderate risk
Naltrexone
Lack of Processing Control
Class II · Moderate risk
Bi-Est8:2/Progesterone/Testosterone 1.0/50 MG/.5MG/ML Cream 30 GM
Lack of Processing Control
Class II · Moderate risk
Bi-Est8:2/Progesterone/Testosterone 1.0/50 MG/.5MG/ML Cream 30 GM tube
Lack of Processing Control
Class II · Moderate risk
Fluorouracil
Lack of Processing Control
Class II · Moderate risk
Testosterone W/Cosmetic HRT Base 100 MG
Lack of Processing Control
Class II · Moderate risk
Estriol Vaginal Cream
Lack of Processing Control
Class II · Moderate risk
Losartan Potassium Tablets
CGMP Deviations: Impurity for N-nitroso-N-methyl-4-aminobutryric Acid (NBMA) detected in active ingredient (API) used to manufacture finished products.
Class II · Moderate risk
Lisinopril Tablets USP
Presence of Foreign Tablet/ Capsule: Product complaint received indicating mix-up of one lisinopril 5mg tablet inside of a 30 mg, 100-count bottle of Lisinopril Tablets.
Class II · Moderate risk
Daytrana (methylphenidate transdermal system)
Defective Delivery System: Out of specification for mechanical peel and shear.
Class II · Moderate risk
Daytrana (methylphenidate transdermal system)
Defective Delivery System: Out of specification for mechanical peel and shear.
Class II · Moderate risk
Daytrana (methylphenidate transdermal system)
Defective Delivery System: Out of specification for mechanical peel and shear.
Class II · Moderate risk
Glycopyrrolate Tablets
Failed Impurities/Degradation Specification: Presence of unknown impurity observed.
Class II · Moderate risk
Losartan Potassium Tablets USP 100 mg
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level
Class II · Moderate risk
Losartan Potassium Tablets USP 50 mg
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level